Nagpur, Maharashtra
GST No. 27AMPPS8870F1Z9
Call 08048989600
Send Enquiry
View Complete details
View Complete details
Minimum Order Quantity: 10 Vial
| Dose/Strength | 3.5 mg |
| Packaging Type | Box |
| Brand | Cadila |
| Manufactured By | Intas Pharmaceuticals |
| Shelf life | 2 years |
Generic Name: Bortezomib
Brand Name: Mibor
Manufacturer: Celon Laboratories Ltd
Strength: 2 mg
Form: Lyophilized Powder for Injection
Multiple Myeloma (a type of blood cancer)
Mantle Cell Lymphoma
Bortezomib is a proteasome inhibitor. It works by blocking the action of proteasomes (cellular complexes that break down proteins). By inhibiting proteasomes, Bortezomib causes an accumulation of proteins in cancer cells, leading to their death.
💡 Dosage & Administration:Administered intravenously (IV) or subcutaneously (SC)
Given in cycles, often in combination with other chemotherapy agents
Dosage adjusted based on patient response and tolerability
Common: Nausea, diarrhea, fatigue, low blood counts (anemia, neutropenia), peripheral neuropathy (nerve pain)
Serious: Cardiac issues, lung problems, liver enzyme elevation
Monitor liver and kidney function
Regular blood tests needed during treatment
Avoid use during pregnancy and breastfeeding
Generic Name: Bortezomib
Brand Name: Bortecad
Manufacturer: Cadila Pharmaceuticals Ltd
Strength: 2.5 mg
Form: Lyophilized Powder for Injection
Multiple Myeloma
Mantle Cell Lymphoma
Functions similarly as a proteasome inhibitor, disrupting normal protein breakdown in cells, leading to stress and eventual death of cancerous cells.
💡 Dosage & Administration:Administered via IV or SC routes
Given on specific days in 21- or 28-day cycles
Adjust dose based on response, blood count, and side effects
Nausea, vomiting, loss of appetite, neuropathy, low platelet counts
More severe effects include breathing problems and liver toxicity
Careful monitoring of neurological symptoms and blood counts
Use with caution in older adults or those with preexisting heart/lung issues
Generic Name: Bortezomib
Brand Name: Borviz
Manufacturer: Intas Pharmaceuticals Ltd
Strength: 3.5 mg
Form: Lyophilized Powder for Injection
Multiple Myeloma
Mantle Cell Lymphoma
Same mechanism as others: proteasome inhibition, leading to apoptosis (cell death) of malignant cells.
💡 Dosage & Administration:Standard recommended dose: 1.3 mg/m² body surface area
Administered via IV or SC injection, usually twice weekly during induction phase
Dose modified in case of side effects or low blood counts
Neuropathy, tiredness, dizziness, anemia, low WBC/platelets
Baseline ECG, liver function, and blood cell counts advised
Monitor for signs of peripheral neuropathy and infections
Additional Information:
View Complete details
Minimum Order Quantity: 10 Vial
| Strength | 120 mg |
| Pack Size | 3 ml |
| Pack Type | Box |
| Brand Name | Docax 120 mg |
| Manufacturer | Neon Labs |
| Usages | inhibits microtubule depolymerization causing apoptosis in cancer cells |
| Country of Origin | Made in India |
Docetaxel
Drug Class:Antineoplastic agent — Taxane group
Indications:Breast cancer
Non-small cell lung cancer (NSCLC)
Prostate cancer
Gastric cancer
Head and neck cancers
Inhibits microtubule depolymerization
Prevents cell division (mitosis), leading to apoptosis (cell death) in cancer cells
Usually administered via intravenous infusion
80 mg dose is considered a moderate dose for some chemotherapy regimens
Dose and cycle depend on cancer type and patient condition
Neutropenia (low white blood cell count)
Peripheral neuropathy (numbness, tingling)
Fluid retention and edema
Nausea, vomiting
Hair loss (alopecia)
Store vials refrigerated at 2°C to 8°C
Protect from light and freezing
Docetaxel
Drug Class:Antineoplastic agent — Taxane group
Indications:Used primarily for dose adjustments or in patients requiring lower doses due to frailty or toxicity risks
Can be part of chemotherapy protocols needing gradual escalation
Same as Celtere (docetaxel) — disrupts microtubule function leading to cancer cell death
Dosage & Administration:IV infusion
20 mg dose for specific dosing needs or initial cycles
Similar to higher doses but generally less severe due to lower amount administered
Refrigerate at 2–8°C, protect from light
Docetaxel
Drug Class:Antineoplastic agent — Taxane group
Indications:Standard dose used in many cancers, including:
Prostate cancer
Breast cancer
NSCLC
Gastric cancer
Same as above — inhibits microtubule depolymerization causing apoptosis in cancer cells
IV infusion
120 mg dose typically used for full standard chemotherapy cycles (e.g., every 3 weeks)
More pronounced than lower doses:
Severe neutropenia
Fluid retention and edema (may require corticosteroid premedication)
Peripheral neuropathy
Nausea and vomiting
Store refrigerated at 2–8°C
Protect from light and freezing
Additional Information:
View Complete details
Minimum Order Quantity: 10 Vial
| Strength | 50 mg |
| Packaging Type | Vial |
| Brand | Fludacel 50 mg |
| Manufacturer | Celon Labs |
| Shelf Life | 1 year |
| Storage Conditions | Protected from moisture and light |
Various manufacturers (specific brand info may vary).
CompositionEach tablet or vial contains Fludarabine Phosphate 10 mg.
IndicationsUsed in the treatment of hematologic malignancies, especially chronic lymphocytic leukemia (CLL).
May be used in lower doses as part of combination chemotherapy regimens.
Sometimes used for patients who require dose adjustments due to tolerance or specific treatment protocols.
Fludarabine is a purine analog that interferes with DNA synthesis by inhibiting DNA polymerase, ribonucleotide reductase, and DNA primase, leading to inhibition of DNA replication and cell death in cancer cells.
Dosage & AdministrationDose varies based on disease and patient condition.
Usually administered intravenously but oral forms may be available.
Lower doses (like 10 mg) may be given for specific regimens or tapering.
Myelosuppression (low blood counts), infections, anemia, thrombocytopenia.
Fatigue, nausea, fever, neurotoxicity in some cases.
Typically available as tablets or injectable solution depending on formulation.
Store as per manufacturer’s guidelines, usually in a cool, dry place.
Popular brands like Natco Pharma and others.
CompositionEach vial or tablet contains Fludarabine Phosphate 50 mg.
IndicationsPrimarily used for treatment of chronic lymphocytic leukemia (CLL) and other blood cancers.
Often used as a standard dose in chemotherapy regimens for hematologic malignancies.
Same as Fludabine 10 mg: Fludarabine inhibits DNA synthesis in rapidly dividing malignant cells, causing apoptosis.
Dosage & AdministrationCommonly administered intravenously as 50 mg per dose.
Dosage schedules depend on treatment protocol and patient condition.
Similar to 10 mg dose but may be more pronounced due to higher dosage: bone marrow suppression, risk of infections, nausea, fatigue.
Available in vials for injection or tablets, typically in packs suitable for chemotherapy cycles.
Store refrigerated or as per specific product instructions, protected from moisture and light.
Additional Information:
View Complete details
Minimum Order Quantity: 10 Vial
| Strength | 500 mg |
| Packaging Type | Box |
| Brand | 5 Flucel 500 mg |
| Manufacturer | Celon Labs |
| Shelf Life | 2 years |
| Storage Conditions | Store in a cool, dry place away from light. Do not freeze. |
Zydus Cadila, India
Each vial contains Fluorouracil 250 mg in 5 mL solution.
Treatment of various cancers including colorectal, breast, gastric, pancreatic, head and neck, esophageal, anal, and bladder cancers.
Used alone or as part of combination chemotherapy.
Fluorouracil is an antimetabolite that inhibits DNA and RNA synthesis in rapidly dividing cancer cells, leading to cell death.
Administered intravenously, usually as bolus or infusion.
Dosage varies according to cancer type, treatment regimen, and patient condition.
Common: nausea, vomiting, diarrhea, mouth sores, hair loss, fatigue, low blood counts.
Serious: cardiotoxicity, neurologic toxicity, infections, hand-foot syndrome, mucositis.
Store in a cool, dry place away from light.
Do not freeze.
Celon Laboratories Ltd., India
Each vial contains Fluorouracil 500 mg in 10 mL solution.
Same as Fluracil 250 mg: colorectal, breast, gastric, pancreatic, head and neck, esophageal, anal, and bladder cancers.
Used intravenously, often in combination chemotherapy.
Same as Fluracil 250 mg: inhibits DNA and RNA synthesis in cancer cells causing cell death.
Intravenous administration with dosage adjusted to patient needs.
Higher dose suitable for more intensive treatment regimens.
Similar to Fluracil 250 mg: gastrointestinal upset, mucositis, fatigue, hair loss, bone marrow suppression.
Higher doses may increase risk of severe side effects.
Store in a cool, dry place away from light.
Do not freeze.
Additional Information:
View Complete details
Minimum Order Quantity: 10 Vial
| Strength | 500 mg |
| Form | Injection |
| Storage Condition | Store in a refrigerator at 2 DegreeC to 8 DegreeC |
Erbitux is a chimeric monoclonal antibody targeting the epidermal growth factor receptor (EGFR).
Used in KRAS wild-type metastatic colorectal cancer (mCRC) and head & neck squamous cell carcinoma (HNSCC).
Works by blocking EGFR signaling, which slows tumor growth and promotes apoptosis.
Each vial contains 100 mg of cetuximab in 20 mL solution (5 mg/mL).
Clear, colorless to pale yellow solution
For intravenous infusion after dilution
Used when lower doses are required (e.g., low BSA or pediatric patients).
Can be used for dose adjustments or combination with 500 mg vial to reach precise dosing.
Metastatic colorectal cancer (with FOLFIRI or alone)
Recurrent/metastatic head & neck cancers (with radiation or platinum-based chemo)
Loading dose: 400 mg/m²
Maintenance dose: 250 mg/m² weekly or 500 mg/m² biweekly
Less convenient for high doses (requires 4–5 vials for 400–500 mg dose)
More time-consuming for preparation
Each vial contains 500 mg of cetuximab in 100 mL solution (5 mg/mL).
Ready-to-infuse solution
Also for IV infusion after dilution
Preferred in most adult dosing regimens
Supports biweekly dosing (500 mg/m² every 2 weeks), which is becoming standard
Improves infusion convenience and reduces waste
Same as 100 mg version, but widely used for standard adult treatment protocols
Fewer vials per dose = faster prep
Reduces volume of excipients per dose
Lower cost per mg compared to 100 mg in some markets
Additional Information:
View Complete details
Minimum Order Quantity: 10 Vial
| Strength | 500 mg |
| Packaging type | Box |
| Form | Injection |
| Storage Condition | 20 DegreeC to 25 DegreeC |
Used in chemotherapy for:
Breast cancer
Lymphomas
Leukemias
Multiple myeloma
Ovarian and lung cancers
Also used as an immunosuppressant in autoimmune diseases (e.g., lupus nephritis, vasculitis)
Alkylating agent causing DNA crosslinking
Interferes with DNA replication and cell division
Leads to apoptosis, mainly affecting rapidly dividing cancer and immune cells
Oral or intravenous
Dosage varies by protocol and disease
Myelosuppression (low blood counts)
Nausea and vomiting
Hair loss
Hemorrhagic cystitis (bladder irritation)
Increased infection risk
Same as Endoxan N but often used for dose titration or in protocols requiring lower doses
If you meant Ifosfamide or another alkylating agent, please confirm.
Otherwise, I cannot provide a reliable detailed description without the exact active ingredient.
Used in low-dose protocols for cancers or autoimmune diseases
May be used for maintenance therapy or dose-adjusted treatments
Store at 20°C to 25°C (room temperature)
Protect from moisture and light
Keep out of reach of children
Additional Information:
View Complete details
Minimum Order Quantity: 10 Vial
| Strength | 400 mg |
| Packaging Type | Vial |
Daratumumab
Brand:Darzalex (by Janssen Pharmaceuticals)
Formulation & Strengths:100 mg vial — used for precise dose adjustments or in patients requiring smaller doses.
400 mg vial — preferred for standard dosing in most adult patients, reducing the number of vials needed.
Darzalex is used to treat multiple myeloma, including:
Newly diagnosed multiple myeloma (in combination with other agents or as monotherapy)
Relapsed or refractory multiple myeloma
Certain types of amyloidosis
Daratumumab is a monoclonal antibody that binds to the CD38 protein found on myeloma cells. This binding:
Triggers immune system attacks on the cancer cells
Causes direct cancer cell death through multiple mechanisms (complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, apoptosis)
Dosage is usually based on 16 mg/kg of body weight.
Darzalex is given as an intravenous infusion (sometimes subcutaneous forms are available).
The number of vials used depends on patient weight and vial strength.
The 400 mg vial is preferred for adults to minimize the number of vials per dose and reduce infusion time.
Infusion-related reactions (fever, chills, cough)
Fatigue
Nausea
Diarrhea
Low blood counts (neutropenia, anemia)
Infections (due to immunosuppression)
Respiratory infections
Store refrigerated at 2°C to 8°C (36°F to 46°F).
Protect from light.
Do not freeze.
Keep in original vial until ready to use.
Additional Information:
View Complete details
Minimum Order Quantity: 10 Vial
| Strength | 50 mg |
| Packaging Type | Vial |
Decitabine
Drug Class:Hypomethylating agent (a cytidine analog)
Indications:Primarily used for myelodysplastic syndromes (MDS)
Also used in some protocols for acute myeloid leukemia (AML), especially in older adults or those unfit for intensive chemotherapy
Incorporates into DNA and inhibits DNA methyltransferase
Leads to hypomethylation of DNA and reactivation of tumor suppressor genes, resulting in slowed cancer cell growth or cell death
IV infusion only
30 mg vial used in dose-adjusted or low-body surface area (BSA) patients
Usually administered once daily for 5 consecutive days in a 28-day cycle
Neutropenia, thrombocytopenia, anemia
Fatigue, nausea, fever
Increased risk of infection
Liver enzyme elevation
Store refrigerated at 2°C to 8°C
Protect from light
Use immediately after reconstitution or per institutional protocol
Decitabine
Drug Class:Hypomethylating agent
Indications:Approved for treatment of MDS
Also commonly used off-label for AML, especially in older patients or those not eligible for intensive therapy
Similar to Decintas—acts on DNA methylation
Promotes differentiation or apoptosis in abnormal hematopoietic cells
IV infusion over 1–3 hours
50 mg vial aligns with standard dosing (20 mg/m²/day × 5 days)
Typically preferred in most treatment regimens due to fewer vials per cycle
Bone marrow suppression (low WBCs, RBCs, platelets)
Gastrointestinal discomfort (nausea, vomiting)
Fever, fatigue
Rare: hepatic toxicity, tumor lysis syndrome
Store refrigerated (2°C to 8°C)
Use immediately after reconstitution or per local protocol
Additional Information:
View Complete details
Minimum Order Quantity: 10 Piece
| Packaging Size | 3x0.6 ml Vial |
| Strength | 6 mg/ 0.6 ml |
| Prescription/Non prescription | Non prescription |
| Form | Injection |
Prevention of chemotherapy-induced neutropenia
Reduces the duration of neutropenia and incidence of febrile neutropenia in cancer patients undergoing cytotoxic chemotherapy
Used in non-myeloid malignancies
Pegfilgrastim is a pegylated form of filgrastim, a granulocyte colony-stimulating factor (G-CSF) analog
Stimulates the production, maturation, and activation of neutrophils in the bone marrow
Pegylation extends the half-life, allowing single-dose per chemotherapy cycle administration
Given as a single subcutaneous injection once per chemotherapy cycle
Typically administered 24 hours after chemotherapy
Bone pain (most common)
Injection site reactions
Headache, fatigue, fever
Rare: splenic rupture, acute respiratory distress syndrome
Store refrigerated at 2–8°C
Do not freeze
Protect from light
Same as Filcad P: prevention and treatment of neutropenia during chemotherapy
Used in various solid tumors and hematologic malignancies
Identical to Filcad P, stimulates neutrophil production
Long-acting due to pegylation, reducing injection frequency
Single SC injection per chemotherapy cycle, ideally 24 hours post-chemo
Similar profile: bone pain, injection site swelling, fever, fatigue
Rare but serious effects include splenic enlargement
Refrigerate at 2–8°C
Avoid freezing and light exposure
Prevention of chemotherapy-induced neutropenia
Shortens neutropenia duration and febrile episodes in cancer patients
Stimulates neutrophil production by binding G-CSF receptors
Pegylation prolongs half-life, enabling once-per-cycle dosing
Single SC injection per chemo cycle, usually 24 hours after chemotherapy
Bone pain, headache, fever, injection site redness
Rare adverse events include splenic rupture and allergic reactions
Store refrigerated at 2–8°C
Do not freeze
Protect from light
Additional Information:
View Complete details
Minimum Order Quantity: 10 Vial
| Strength | 15mg |
| Packaging Type | Vial |
| Country of Origin | Made in India |
Generic Name: Thiotepa
Manufacturer: Emcure Pharmaceuticals Ltd
Formulation: Lyophilized Powder for Injection
Strength: 15 mg/vial
Preparation for hematopoietic stem cell transplantation (HSCT)
Treatment of:
Breast cancer
Ovarian cancer
Bladder cancer
Neoplastic diseases involving serosal cavities
Malignant effusions caused by tumors
Tepapro (Thiotepa) is an alkylating agent. It works by interfering with the DNA replication process, causing cross-linking of DNA strands, which leads to the death of rapidly growing cancer cells.
💊 Dosage & AdministrationGiven as an intravenous infusion under medical supervision.
Dosage is individualized based on patient’s body surface area, condition, and treatment protocol.
Neutropenia (low white blood cells)
Anemia
Thrombocytopenia (low platelets)
Mucosal inflammation
Diarrhea
Rash
Liver enzyme elevation
Hemorrhage
Store below 30°C
Protect from light and moisture
Generic Name: Thiotepa
Manufacturer: Samarth Life Sciences Pvt. Ltd
Formulation: Lyophilized Powder for Injection
Strength: 15 mg/vial
Part of conditioning regimen for HSCT
Used in the treatment of:
Breast cancer
Ovarian cancer
Bladder cancer
Serosal cavity involvement with malignancy
Malignant pleural/peritoneal effusions
Thiopta contains Thiotepa, which is an alkylating chemotherapeutic agent. It disrupts DNA function by forming cross-links between DNA strands, preventing cell division and resulting in cancer cell death.
💊 Dosage & AdministrationAdministered via intravenous infusion
Requires dilution and reconstitution before use
Only under the supervision of qualified oncology personnel
Nausea and vomiting
Loss of appetite
Abdominal pain
Injection site discomfort
Fatigue
Hair thinning
Mucositis
Store between 2°C and 8°C
Protect from light
Additional Information:
View Complete details
Minimum Order Quantity: 10 Vial
| Strength | 50 mg |
| Packaging Type | Vial |
Generic Name: Cetuximab
Brand Name: Biomab EGFR
Drug Class: Monoclonal antibody (targeted therapy)
Mechanism of Action:
Cetuximab is a chimeric (mouse/human) monoclonal antibody that binds specifically to the extracellular domain of the epidermal growth factor receptor (EGFR). By blocking EGFR activation, it inhibits downstream signaling pathways involved in cancer cell proliferation, survival, angiogenesis, and metastasis. This results in the suppression of tumor growth.
Colorectal Cancer:
Used in combination with chemotherapy for treatment of metastatic colorectal cancer (mCRC) with wild-type KRAS gene (EGFR-positive).
Head and Neck Squamous Cell Carcinoma (HNSCC):
Used as a single agent or with radiation therapy in locally or regionally advanced squamous cell carcinoma of the head and neck.
May be used in other cancers expressing EGFR as per oncologist discretion.
Form: Intravenous infusion
Strength: 50 mg vial (usually comes in vials of 50 mg, 100 mg, or 200 mg for preparation)
Initial Dose: Typically 400 mg/m² infused over 2 hours.
Maintenance Dose: 250 mg/m² infused weekly over 1 hour.
Dosage and schedule may vary based on cancer type, patient tolerance, and treatment protocol.
Requires dilution and administration via intravenous infusion by a healthcare professional.
Pre-medication with antihistamines (e.g., diphenhydramine) and corticosteroids may be given to reduce infusion-related reactions.
Half-life: Approximately 112 hours (about 4.5 days) after multiple doses.
Clearance is dose-dependent and decreases with repeated dosing.
Metabolized via protein degradation pathways.
Common:
Acneiform rash (skin rash resembling acne, often a marker of efficacy)
Infusion-related reactions (fever, chills, hypotension)
Fatigue
Diarrhea
Nausea and vomiting
Serious:
Severe infusion reactions (anaphylaxis)
Electrolyte abnormalities (hypomagnesemia)
Cardiac arrest (rare)
Interstitial lung disease (rare)
Monitor closely for infusion reactions during and after infusion.
Assess magnesium, potassium, and calcium levels regularly during therapy.
Discontinue therapy for severe or life-threatening reactions.
Use caution in patients with pre-existing cardiac conditions.
Store vials refrigerated at 2–8°C (do not freeze).
Protect from light.
Use within specified time after reconstitution/preparation.
Additional Information:
View Complete details
Minimum Order Quantity: 10 Vial
| Country of Origin | Made in India |
Filgrastim 500 mcg
A recombinant human Granulocyte Colony-Stimulating Factor (G-CSF)
Methylcobalamin (Vitamin B12)
Active form of Vitamin B12, essential for nerve health and hematopoiesis
Filgrastim: Hematopoietic Growth Factor
Methylcobalamin: Vitamin Supplement
Filgrastim:
Stimulates the bone marrow to increase production of neutrophils (a type of white blood cell), helping to fight infection and recover neutrophil count after chemotherapy or bone marrow suppression.
Methylcobalamin:
Supports DNA synthesis and red blood cell formation, and improves nerve regeneration and function.
Prevention and treatment of neutropenia caused by chemotherapy or bone marrow transplantation
Treatment of febrile neutropenia
Support in patients with aplastic anemia or other bone marrow disorders
Used in peripheral neuropathy or vitamin B12 deficiency states due to methylcobalamin component
Route: Subcutaneous injection (most common) or intravenous infusion
Filgrastim dose: Typically 5 mcg/kg/day, adjusted per patient condition
Methylcobalamin dose: 500 mcg per injection as per formulation
Duration varies according to clinical response and physician’s guidance
Bone pain (common with Filgrastim)
Injection site reactions
Headache, fatigue
Rare: Splenic rupture, allergic reactions
Methylcobalamin generally well tolerated
Store refrigerated at 2–8°C
Protect from light
Do not freeze
Monitor complete blood counts regularly during therapy
Use cautiously in patients with sickle cell disease or other hematologic disorders
Not for use in patients with hypersensitivity to any components
Additional Information:
View Complete details
Minimum Order Quantity: 10 Vial
| Strength | 2.5 mg / 2.5 ml |
| Packaging Type | Vial |
Generic Name: Topotecan
Formulation: Injectable solution or capsules (depending on brand)
Strength: 2.5 mg (usually vial strength for injection)
Drug Class: Topoisomerase I inhibitor (chemotherapy agent)
Treatment of small cell lung cancer (SCLC)
Treatment of ovarian cancer after failure of first-line chemotherapy
Sometimes used in cervical cancer and other solid tumors
Topotecan inhibits topoisomerase I, an enzyme responsible for relieving DNA supercoiling during replication. By stabilizing the complex between topoisomerase I and DNA, it causes DNA strand breaks, leading to cancer cell death.
💊 Dosage & AdministrationAdministered intravenously over 30 minutes, typically daily for 5 consecutive days every 21 days.
Dosage adjusted based on body surface area and patient tolerance.
Myelosuppression (especially neutropenia, anemia, thrombocytopenia)
Nausea and vomiting
Fatigue and weakness
Diarrhea
Hair thinning or loss
Store at 2°C to 8°C (refrigerated)
Protect from light
Generic Name: Topotecan (likely same active ingredient)
Formulation: Usually injectable or oral form (brand-specific)
Strength: Variable, commonly available in 2.5 mg vials for injection
Same as Topotec (used in ovarian, small cell lung, and cervical cancers)
Identical to Topotec, as it contains the same active ingredient, Topotecan.
Similar dosing regimen to Topotec.
Administered intravenously or orally as per protocol.
Comparable safety profile to Topotec.
Monitor blood counts closely.
Refrigerated storage recommended.
Follow manufacturer guidelines.
Topotec 2.5 mg is more widely recognized and prescribed because it is a well-established brand or generic.
Topowin may be a brand or alternative generic; usage depends on regional availability and hospital preference.
Additional Information:
View Complete details
| Strength | 50 mg |
| Packaging Type | Box |
| Country of Origin | Made in India |
| Brand Name: | Biomab |
| Contents: | Nimotuzumab 50mg INjection |
| Form: | Injection |
| Manufacturer | Biocon |
| Packing: | Price per Vial 10ml |
View Complete details
| Strength | 10000 IU |
| Packaging Size | Tube |
| Packaging Type | box |
| Country of Origin | Made in India |
View Complete details
| Strength | 100 mg/5 ml |
| Form | Syrup |
| Usage/Application | Clinic |
| Prescription/Non prescription | Prescription |
| Packaging Type | Box |
| SKU | mm1496 |
|---|---|
| Best_Value | N/A |
| US Brand Name | |
| Strength | 100mg/5ml |
| Generic Name | Irinotecan |
| Pharmaceutical Form | Vial/s |
| Per Unit Pharmaceutical Form | Vial |
| Manufacturer | Fresenius Kabi |
| Shipped From | India |
View Complete details